SCHEMBL7996776

SCHEMBL7996776

CC(C)Nc1cc(Cl)nc(C(F)(F)F)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.42
CYP1A2 P05177 2/20 0.40
KDM4E B2RXH2 2/20 0.36
ATM Q13315 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CCNE2 O96020 3/20 0.33
CCNE1 P24864 3/20 0.33
CDK2 P24941 3/20 0.33
CDK4 P11802 2/20 0.33
CCND1 P24385 2/20 0.33
GAA P10253 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15357776 0.88 CYP1A2 (0.36) TLR7CYP1A2KDM4EATMCYP2C9
SCHEMBL25867803 0.81 TLR7 (0.43) TLR7CYP1A2HTTTRPM8CCNE2
SCHEMBL15360303 0.80 KDM4E (0.36) CYP1A2KDM4ECYP2C19ALDH1A1HTT
SCHEMBL1748325 0.80 GAA (0.48) ALDH1A1TRPM8NPSR1CDK2GAA
SCHEMBL25083887 0.77 TLR7 (0.40) TLR7CYP1A2KDM4EATMCYP2C9
SCHEMBL26894289 0.74 MEN1 (0.39) CYP1A2KDM4EATMCYP2C9CYP2C19
SCHEMBL231621 0.74 HSD17B10 (0.35) KDM4EALDH1A1HTTNPSR1CCNE2
SCHEMBL9493382 0.74 GAA (0.52) CYP1A2KDM4EATMCYP2C9CYP2C19
SCHEMBL12411085 0.74 MEN1 (0.44) KDM4EALDH1A1TRPM8NPSR1CDK2
SCHEMBL29394574 0.73 HRH4 (0.50) KDM4ECYP2C19ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-18 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed
WO-2023028338-A2 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
WO-2009143156-A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SEPRACOR INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A TLR7 3207/4885CYP1A2 4379/4885KDM4E 4460/4885
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD TLR7 2012/4885CYP1A2 61/4885KDM4E 3088/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A TLR7 1917/4885CYP1A2 3113/4885KDM4E 4040/4885
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS M6PR, ASGR1, IGF2R TLR7 2581/4885CYP1A2 4602/4885KDM4E 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.